BMYMP Stock Bristol-Myers Squibb (BMYMP, $760) RSI Indicator left the oversold zone on July 14, 2025

GET DAILY SIGNALS

Get AI intraday signals

BMYMP - Bristol-Myers Squibb Co.

RSI signal

View

Odds of UP Trend

Price: $760

Daily change: -$41.01 (-5.12%)

Daily volume: 5

Industry: Pharmaceuticals: Major

BMYMP's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BMYMP turned positive on August 13, 2025. Looking at past instances where BMYMP's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMYMP's RSI Indicator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 14, 2025. You may want to consider a long position or call options on BMYMP as a result. In of 59 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

BMYMP moved below its 50-day moving average on July 31, 2025 date and that indicates a change from an upward trend to a downward trend.

The Aroon Indicator for BMYMP entered a downward trend on July 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (8.904). BMYMP has a moderately low P/E Ratio (0.000) as compared to the industry average of (23.460). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.835). BMYMP has a moderately low Dividend Yield (0.002) as compared to the industry average of (0.028). BMYMP's P/S Ratio (0.000) is slightly lower than the industry average of (3.346).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BMYMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMYMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.